HIF1A and neoplasm: Although the same objection raised on HIF-1α inhibitors, i.e., the low specificity and the toxicity on non-transformed tissues, can be applied to glycolysis inhibitors, the different dependence from glycolysis between tumor and non-tumor cells make the former more susceptible to 2-DG cytotoxicity, used at dosages minimally affecting normal cells.